Bausch & Lomb Incorporated
Rochester, New York, 14609, United States
NCT Number: NCT00905762
The purpose of this study is to assess the concentration of besifloxacin compared to gatifloxacin and moxifloxacin in human conjunctival tissue, following a single drop of the drug instilled topically into the study eye. Conjunctival biopsies will be performed at specified time points, followed by the use of loteprednol etabonate/tobramycin ophthalmic suspension four times a day for 5 days.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Rochester, New York, 14609, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Gatifloxacin 0.3% one drop instilled into study eye at visit 2.
Moxifloxacin 0.5% one drop instilled into study eye at visit 2.
Besifloxacin 0.6% one drop instilled into study eye at visit 2.
Other names: Besivance
Time frame: Biopsies collected at specified time points from 15 minutes to 24 hours
Time frame: Day -14 through Day 6(+/-1)
Time frame: Day -14 through Day 6 (+/-)
Bausch & Lomb Incorporated
Industry
A Single-Center, Randomized, Masked Study Comparing the Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After a Single Topical Instillation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02206178
Healthy
Clermont-Ferrand, France
View Trial DetailsNCT07534020
Healthy
Addison, Illinois, United States
View Trial DetailsNCT07724015
Healthy
Jaén, Spain
View Trial DetailsNCT07404254
Beverage Intake, Caffeine
San Francisco, California, United States
View Trial Details